Congratulations to our client First Tracks Biotherapeutics (TRAX) for appointing Carlos A. Garcia as Senior Vice President of CMC.
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.
C1 Team: Tom Murphy & Leo Cain